Predictors of fibrostenotic Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 9, 2011, Pages 2000-2007

  Rieder, Florian ^a   Lawrance, Ian C ^b,c   Leite, Andre ^d   Sans, Miquel ^e  

^a Digestive Disease Institute   (United States)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

biomarker; Crohn's disease; fibrosis; prediction; stricture

Indexed keywords

AZATHIOPRINE; BASIC FIBROBLAST GROWTH FACTOR; C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLLAGEN TYPE 3; CORTICOSTEROID; SCLEROPROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CROHN DISEASE; DISEASE MARKER; FIBROGENESIS; FIBROSTENOTIC CROHN DISEASE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW;

CROHN DISEASE; FIBROSIS; HUMANS; PROGNOSIS;

EID: 80051548464     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21627     Document Type: Review

References (87)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250. (Pubitemid 34784976)
2. Van Assche G, Geboes K, Rutgeerts P,. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis. 2004; 10: 55-60. (Pubitemid 38072447)
3. Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003; 186: 514-518. (Pubitemid 37352838)
4. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99: 956-963. (Pubitemid 20338451)
5. Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg. 2001; 192: 330-337; discussion 337-338.
6. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777-782. (Pubitemid 33096034)
7. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667. (Pubitemid 351284485)
8. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
9. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603-606. (Pubitemid 32531409)
10. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603. (Pubitemid 32531408)
11. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002; 359: 1661-1665. (Pubitemid 34518526)
12. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004; 36: 471-475. (Pubitemid 38620030)
13. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004; 36: 476-480. (Pubitemid 38620031)
14. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010; 42: 1118-1125.
15. Helio T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut. 2003; 52: 558-562. (Pubitemid 36363411)
16. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002; 122: 867-874. (Pubitemid 34267268)
17. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002; 122: 854-866. (Pubitemid 34267267)
18. Vavassori P, Borgiani P, D'Apice MR, et al. 3020insC mutation within the NOD2 gene in Crohn's disease: frequency and association with clinical pattern in an Italian population. Dig Liver Dis. 2002; 34: 153. (Pubitemid 34202078)
19. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003; 9: 281-289. (Pubitemid 37161747)
20. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002; 70: 845-857. (Pubitemid 34259301)
21. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002; 123: 679-688. (Pubitemid 34977073)
22. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005; 242: 693-700. (Pubitemid 41567125)
23. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004; 99: 2393-2404. (Pubitemid 40039371)
24. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, et al. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2007; 13: 2960-2966. (Pubitemid 47028884)
25. Weersma RK, Stokkers PC, Cleynen I, et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol. 2009; 104: 630-638.
26. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol. 2009; 7: 972-980 e972.
27. Figueroa CD, Cleynen I, Franke A, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype, but do not predict it. Results from the IBDChip European Project. Gastroenterology. 2010; 138:(suppl 1): S677.
28. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008; 103: 3082-3093.
29. Louis E, Reenaers C, Belaiche J,. Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease? Inflamm Bowel Dis. 2008; 14 (suppl 2): S59-60.
30. Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009; 15: 3504-3510.
31. Leong RW, Lau JY, Sung JJ,. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis. 2004; 10: 646-651. (Pubitemid 39276475)
32. Chow DK, Leong RW, Lai LH, et al. Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm Bowel Dis. 2008; 14: 536-541. (Pubitemid 351571834)
33. Loly C, Belaiche J, Louis E,. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008; 43: 948-954.
34. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656. (Pubitemid 43374514)
35. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
36. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003; 52: 552-557. (Pubitemid 36363410)
37. Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 371-383.
38. Cosnes J, Carbonnel F, Carrat F, et al. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther. 1999; 13: 1403-1411. (Pubitemid 29516251)
39. Unkart JT, Anderson L, Li E, et al. Risk factors for surgical recurrence after ileocolic resection of Crohn's disease. Dis Colon Rectum. 2008; 51: 1211-1216.
40. Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007; 102: 577-588. (Pubitemid 46328158)
41. Bodily KD, Fletcher JG, Solem CA, et al. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT enterography-correlation with endoscopic and histologic findings of inflammation. Radiology. 2006; 238: 505-516. (Pubitemid 43134363)
42. Low RN, Sebrechts CP, Politoske DA, et al. Crohn disease with endoscopic correlation: single-shot fast spin-echo and gadolinium-enhanced fat-suppressed spoiled gradient-echo MR imaging. Radiology. 2002; 222: 652-660. (Pubitemid 34215209)
43. Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2010 [Epub ahead of print].
44. Fiorino F, Pizzini FB, Beltramello A, et al. MRI performed after intratympanic gadolinium administration in patients with Meniere's disease: correlation with symptoms and signs. Eur Arch Otorhinolaryngol. 2010 [Epub ahead of print].
45. Lawrance IC, Welman CJ, Shipman P, et al. Correlation of MRI-determined small bowel Crohn's disease categories with medical response and surgical pathology. World J Gastroenterol. 2009; 15: 3367-3375.
46. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47: 487-496.
47. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128: 2020-2028. (Pubitemid 40824710)
48. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004; 126: 414-424. (Pubitemid 38182298)
49. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008; 103: 665-681. (Pubitemid 351405992)
50. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007; 56: 1394-1403. (Pubitemid 47517833)
51. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2010; 16: 263-274.
52. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006; 131: 366-378. (Pubitemid 44142445)
53. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009; 104: 1426-1434.
54. Simondi D, Mengozzi G, Betteto S, et al. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 645-651. (Pubitemid 351742981)
55. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006; 101: 645-652. (Pubitemid 43340944)
56. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008; 10: 1105-1111.
57. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010; 16: 1367-1375.
58. Shine B, Gould J, Campbell C, et al. Serum C-reactive protein in normal and infected neonates. Clin Chim Acta. 1985; 148: 97-103. (Pubitemid 15034645)
59. Beattie RM, Walker-Smith JA, Murch SH,. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child. 1995; 73: 354-355.
60. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002; 14: 409-412. (Pubitemid 34439041)
61. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982; 12: 351-359. (Pubitemid 12024511)
62. Andre C, Descos L, Vignal J, et al. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease. Scott Med J. 1983; 28: 26-29. (Pubitemid 13181239)
63. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988; 10: 401-405.
64. Linskens RK, van Bodegraven AA, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001; 46: 644-648. (Pubitemid 32299823)
65. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996; 38: 905-910. (Pubitemid 26231777)
66. Tromm A, Tromm CD, Huppe D, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol. 1992; 27: 774-778.
67. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006; 12: 551-557. (Pubitemid 43977735)
68. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002; 37: 818-824. (Pubitemid 34836819)
69. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57: 1518-1523.
70. Rieder F, Fiocchi C,. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev. 2009; 6: 228-235.
71. Loeschke K, Kaltenthaler P,. [Procollagen-III-peptide in the serum of patients with Crohn disease.] Z Gastroenterol. 1989; 27: 137-139. (Pubitemid 19094160)
72. De Simone M, Cioffi U, Contessini-Avesani E, et al. Elevated serum procollagen type III peptide in splanchnic and peripheral circulation of patients with inflammatory bowel disease submitted to surgery. BMC Gastroenterol. 2004; 4: 29.
73. Kjeldsen J, Schaffalitzky de Muckadell OB, Junker P,. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Gut. 1995; 37: 805-810.
74. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol. 2003; 56: 817-820. (Pubitemid 37386567)
75. Allan A, Wyke J, Allan RN, et al. Plasma fibronectin in Crohn's disease. Gut. 1989; 30: 627-633. (Pubitemid 19147075)
76. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis. 2003; 18: 254-259. (Pubitemid 36764173)
77. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis. 2004; 10: 573-577. (Pubitemid 39276464)
78. Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004; 99: 2186-2194. (Pubitemid 39524710)
79. Lawrance IC, Hall A, Leong R, et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis. 2005; 11: 890-897. (Pubitemid 41428847)
80. Luo CH, Wexner SD, Liu QS, et al. The differences between American and Chinese patients with Crohn's disease. Colorectal Dis. 2009 [Epub ahead of print].
81. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000; 119: 895-902.
82. Szamosi T, Banai J, Lakatos L, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010; 22: 872-879.
83. Papay P, Reinisch W, Ho E, et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol. 2010; 105: 1158-1164.
84. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442; quiz 464. (Pubitemid 43261469)
85. van Assche G, Vermeire S, Rutgeerts P,. Mucosal healing and anti TNFs in IBD. Curr Drug Targets. 2010; 11: 227-233.
86. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 1493-1499.
87. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128: 862-869. (Pubitemid 40523539)